BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:50 PM
 | 
Mar 10, 2010
 |  BC Extra  |  Company News

Transgene grants Novartis TG4010 option

Transgene S.A. (Euronext:TNG) granted Novartis AG (NYSE:NVS; SIX:NOVN) an option to obtain exclusive, worldwide rights to TG4010. Transgene plans to start a Phase IIb/III trial of TG4010...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >